Co-administration of aprotinin and epsilon-aminocaproic acid during cardiopulmonary bypass in a swine model

Journal of Extra-Corporeal Technology

Volumn 32, Issue 4, 2000, Pages 196-206

  Vang, S N ^a   Stammers, A H ^a   Mejak, B L ^a   Rauch, E D ^a   Viessman, T W ^a   Bruda, N L ^a   Yang, T ^a  

^a Mercy Medical Center Sioux City   (United States)

Author keywords

Aprotinin; Cardiopulmonary bypass; Epsilon aminocaproic acid; Fibrinolysis; Thrombosis

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG MIXTURE; NONHUMAN; SWINE; THROMBOELASTOGRAPHY; THROMBOGENICITY;

EID: 0034543625     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hemostasis changes during cardiopulmonary bypass surgery
2. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells
3. Factors influencing haemostasis and blood transfusion in cardiac surgery
4. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery
5. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator
6. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
7. Thrombin generation during cardiac surgery: Is heparin the ideal anticoagulant?
8. Approaches and techniques to minimize blood transfusion
9. Drugs to minimize perioperarive blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators
10. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding
11. Cost-benefit and efficacy of aprotinin compared with ε-aminocaproic acid in patients having repeated cardiac operations
12. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents
13. The role of epsilon-aminocaproic acid in reducing bleeding after cardiac operation: A double-blind randomized study
14. Prophylactic tranexamic acid decreased bleeding after cardiac operations
15. Prophylactic -aminocaproic acid (AMICAR) administration minimizes blood replacement therapy during cardiac surgery
16. Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass
17. Blood contact activation: Pathophysiological effects and therapeutic approaches
18. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass
19. Factor XII-induced fibrinolysis: Studies on the separation on prekallikrein, plasminogen proactivator, and factor XI in human plasma
20. Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells
21. Hemostasis monitoring during cardiac surgery
22. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery
23. Aprotinin prevents bleeding and has effects on platelets and fibrinolysis
24. Decreased postoperative drainage with addition of -aminocaproic acid before cardiopulmonary bypass
25. The intraoperative use of Amicar to reduce bleeding associated with open heart surgery
26. The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery
27. Prophylactic tranexamic acid and -aminocaproic acid for primary myocardial revascularization
28. High-dose ε-aminocaproic acid versus aprotinin: Antifibrinolytic efficacy in first-time coronary operations
29. Effects of aprotinin on the need for blood transfusions after repeat open-heart surgery
30. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid
31. Obstruction of the renal pelvis due to an insoluble blood clot after epsilonaminocaproic acid therapy: Resolution with intraureteral streptokinase instillations
32. Epsilon aminocaproic acid: A dangerous weapon
33. Complications of therapy with epsilonaminocaproic acid
34. Glomerular capillary thrombosis and acute renal failure after epsilon amino caproic acid therapy
35. Intraoperative coronary thrombosis: Can aprotinin and protamine be incriminated?
36. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest
37. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study
38. Intraoperative coronary thrombosis: Can apro tinin be incriminated?
39. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting